GI262570: Phase III

In a 376-patient Phase III study, once daily doses of 1-10 mg GI262570 produced a significant improvement from baseline in fasting serum glucose and HbA1c levels at 12 weeks compared to placebo. The 10 mg dose gave a 1.9 percent reduction in HbA1c levels. The product also significantly lowered triglycerides and increased HDL cholesterol compared to placebo. ...